RxDoctor Payments Data

Frank Barrows

Pediatric Endocrinology · Shrewsbury, NJNPI 1427025535

Payments from drug & device makers

What this record shows

The money is spread across several categories — consulting fees (50.0%), food and beverage and education — rather than concentrated in one kind of arrangement. 21 manufacturers reported payments, led by Novo Nordisk at 56.6% of the total. Reporting peaked in 2022 at $1,483 and has fallen 89.7% since, to $153 in 2025.

$2,718in general payments, 2019–2025

Across 73 payments — averaging $37.24 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$2K
  • Medtronic$258
  • Pfizer$114
  • Insulet Corporation$113
  • Abbott$108
  • Ascendis Pharma Endocrinology Inc$92
  • plus $493 from 15 others

What the payments were for

  • Consulting fees$1,35950%
  • Food & beverage$1,34549%
  • Education$151%

General payments by program year

19
20
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,718 in reported general payments places this provider in the 70th percentile of 59 pediatric endocrinology providers in New Jersey.

See all pediatric endocrinology providers in New Jersey

Other pediatric endocrinology in Shrewsbury

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →